Unicycive receives Nasdaq deficiency notices for bid price and market value

Unicycive Therapeutics, Inc.

On July 9, 2024, Nasdaq notified Unicycive that stock bid price closed below $1.00 for 30 consecutive days, violating Listing Rule 5550(a)(2).
On July 11, 2024, Nasdaq notified that Market Value of Listed Securities was below $35M for 30 consecutive days, violating Rule 5550(b)(2).
Company has 180 calendar days (until Jan 6/7, 2025) to regain compliance for each deficiency by meeting thresholds for 10 consecutive business days.
If non-compliant after grace period, Nasdaq may delist; company can appeal. No assurance of maintaining listing.
Stock continues trading on Nasdaq Capital Market under UNCY; company monitoring and evaluating options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.